Status:
COMPLETED
NIDDM and IR in Combination Therapy for CHC
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Chronic Hepatitis C
Insulin Resistance
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The influence of insulin sensitivity and glucose tolerance on the effects of antiviral therapy for HCV remains unclear. The aim of the present study was (1) To elucidate the clinical and virological f...
Detailed Description
Total 300 treatment-naïve chronic hepatitis C patients will be enrolled. The prevalence of NIDDM, IGT and IR will be explored in this hospital-based study among the clinically defined chronic hepatiti...
Eligibility Criteria
Inclusion
- Chronic hepatitis C patients with positive anti-HCV for more than 6 months and HCV RNA
- No overt hepatic failure or decompensated liver cirrhosis (Child-Pugh class B or C) or hepatocellular carcinoma.
Exclusion
- Positive for hepatitis B surface antigen (HBsAg)or with concomitant human immunodeficiency virus infection
- With other types of hepatitis including autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, Wilson's disease, alpha 1-antitrypsin deficiency
- Current or past history of alcohol abuse (80 mL ethanol per day)
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00687999
Start Date
December 1 2005
End Date
June 1 2008
Last Update
August 6 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 807